T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Altria Group
MO
$107B
| $271M | 0.03% |
4,705,567
-465,350
| -9% | -$28.1M |
|
377
StoneX
SNEX
$8.37B
| $271M | 0.03% |
6,415,803
+989,485
| +18% | +$41.5M |
|
378
Global X Copper Miners ETF NEW
COPX
$8.22B
| $271M | 0.03% |
3,777,913
+148,930
| +4% | +$9.54M |
|
379
Revolution Medicines
RVMD
$44B
| $271M | 0.03% |
3,404,717
-468,989
| -12% | -$30.8M |
|
380
Reliance Steel & Aluminium
RS
$21.8B
| $270M | 0.03% |
934,666
-27,739
| -3% | -$7.79M |
|
381
Nike
NKE
$60.1B
| $269M | 0.03% |
4,222,897
-235,356
| -5% | -$15.3M |
|
382
CRH
CRH
$65.2B
| $267M | 0.03% |
2,140,571
+1,586,810
| +287% | +$189M |
|
383
Hanover Insurance
THG
$7.74B
| $266M | 0.03% |
1,456,954
-172,191
| -11% | -$31M |
|
384
Marqeta
MQ
$1.63B
| $266M | 0.03% |
14,008,609
-7,332
| -0.1% | -$141K |
|
385
Neurocrine Biosciences
NBIX
$15.9B
| $266M | 0.03% |
1,872,240
-994,491
| -35% | -$144M |
|
386
Verizon
VZ
$195B
| $265M | 0.03% |
6,512,366
-1,097,965
| -14% | -$44.5M |
|
387
nVent Electric
NVT
$27.7B
| $263M | 0.03% |
2,577,555
+2,019,483
| +362% | +$210M |
|
388
HCA Healthcare
HCA
$89.8B
| $262M | 0.03% |
561,590
+9,139
| +2% | +$4.24M |
|
389
Enbridge
ENB
$112B
| $260M | 0.03% |
5,439,590
-322,792
| -6% | -$15.4M |
|
390
Sensata Technologies
ST
$6.72B
| $259M | 0.03% |
7,788,581
-1,021,742
| -12% | -$32.7M |
|
391
Assurant
AIZ
$13.9B
| $256M | 0.03% |
1,063,433
-94,399
| -8% | -$21.1M |
|
392
Waters Corp
WAT
$40.9B
| $255M | 0.03% |
671,103
+561,047
| +510% | +$206M |
|
393
CenterPoint Energy
CNP
$26.7B
| $255M | 0.03% |
6,645,302
-517,760
| -7% | -$20.2M |
|
394
Healthcare Realty
HR
$6.58B
| $254M | 0.03% |
14,978,751
-347,293
| -2% | -$6.18M |
|
395
Tractor Supply
TSCO
$19B
| $252M | 0.03% |
5,046,977
+1,595,803
| +46% | +$85.9M |
|
396
Alkermes
ALKS
$8.44B
| $252M | 0.03% |
8,998,963
-1,239,394
| -12% | -$37.1M |
|
|
CYBR
397
DELISTED
CyberArk
CYBR
| $251M | 0.03% |
563,699
-703,375
| -56% | -$339M |
|
398
CMS Energy
CMS
$22B
| $251M | 0.03% |
3,583,397
-2,513,205
| -41% | -$183M |
|
399
RBC Bearings
RBC
$17.6B
| $250M | 0.03% |
558,418
-47,939
| -8% | -$20.3M |
|
400
Grupo Aeroportuario del Pacifico
PAC
$12.8B
| $250M | 0.03% |
948,509
-150,586
| -14% | -$35M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.